World's Best Scientists 2026 revealed!
Howard L. Kaufman

Howard L. Kaufman

D-Index & Metrics

Immunology

D-Index
85
Citations
34317
World Ranking
1301
National Ranking
676

Medicine

D-Index
85
Citations
34572
World Ranking
14424
National Ranking
7298

Overview

Howard L. Kaufman is affiliated with Harvard University in the United States. Their research primarily focuses on Medicine and Biochemistry, Genetics and Molecular Biology, with significant contributions to Oncology, Immunology, Genetics, Molecular Biology, and Epidemiology.

Their scholarly work spans several key topics within biomedical research, including:

  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Virus-based gene therapy research
  • Nonmelanoma Skin Cancer Studies
  • Cutaneous Melanoma Detection and Management
  • Viral Infectious Diseases and Gene Expression in Insects

Among their recent publications are:

  • Therapy with oncolytic viruses: progress and challenges, 2023, Nature Reviews Clinical Oncology
  • Clinical landscape of oncolytic virus research in 2020, 2020, Journal for ImmunoTherapy of Cancer
  • Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma, 2022, New England Journal of Medicine
  • Immunotherapy for Non-melanoma Skin Cancer, 2021, Current Oncology Reports
  • Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19), 2020, Journal of Translational Medicine

They frequently collaborate with other researchers. Their notable co-authors include:

  • David M. Miller (23 collaborations)
  • Kevin S. Emerick (20 collaborations)
  • Sophia Z. Shalhout (19 collaborations)
  • Sailaja Battula (15 collaborations)
  • Ann W. Silk (11 collaborations)

Kaufman's publications often appear in specific venues with repeated contributions. The most frequent publication venues are:

  • Regular and Young Investigator Award Abstracts (14 publications)
  • Journal for ImmunoTherapy of Cancer (10 publications)
  • Journal of Cutaneous Oncology (9 publications)
  • Journal of Clinical Oncology (6 publications)
  • Cancer Research (5 publications)

Best Publications

  • Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

    Robert H.I. Andtbacka;Howard L. Kaufman;Frances Collichio;Thomas Amatruda

  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    I. Puzanov;A. Diab;K. Abdallah;C. O. Bingham

  • Oncolytic viruses: a new class of immunotherapy drugs

    Howard L. Kaufman;Frederick J. Kohlhapp;Andrew Zloza

  • Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

    Howard L. Kaufman;Jeffery Russell;Omid Hamid;Shailender Bhatia

  • gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

    Douglas J. Schwartzentruber;David H. Lawson;Jon M. Richards;Robert M. Conry

  • Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Lorenzo Galluzzi;Ilio Vitale;Sarah Warren;Sandy Adjemian

  • Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

    Neil N. Senzer;Howard L. Kaufman;Thomas Amatruda;Mike Nemunaitis

  • Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

    Jason Chesney;Igor Puzanov;Frances Collichio;Parminder Singh

  • Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

    Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino

  • Integrating oncolytic viruses in combination cancer immunotherapy

    Praveen K. Bommareddy;Megha Shettigar;Howard L. Kaufman

  • Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.

    Howard L. Kaufman;Dae Won Kim;Gail DeRaffele;Josephine Mitcham

  • Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

    Igor Puzanov;Mohammed M. Milhem;David Minor;Omid Hamid

  • Therapy with oncolytic viruses: progress and challenges

    Unknown

  • Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

    Robert H. I. Andtbacka;Frances Collichio;Kevin J. Harrington;Mark R. Middleton

  • Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.

    Wenqian Zhang;Ying Yu;Falk Hertwig;Falk Hertwig;Jean Thierry-Mieg

  • Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma

    Giovanni C. Cesana;Gail DeRaffele;Seth Cohen;Dorota Moroziewicz

  • Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

    Janice M. Mehnert;Anshuman Panda;Hua Zhong;Hua Zhong;Kim Hirshfield

  • Combination immunotherapy: a road map

    Patrick A. Ott;F. Stephen Hodi;Howard L. Kaufman;Jon M. Wigginton

  • Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial

    Sandra P. D’Angelo;Jeffery Russell;Céleste Lebbé;Bartosz Chmielowski

  • Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy.

    Hasan Rehman;Ann W. Silk;Michael P. Kane;Howard L. Kaufman

  • Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule.

    Heidi Hörig;David S. Lee;William Conkright;Joe Divito

Frequent Co-Authors

David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Michael A. Morse
Michael A. Morse Duke University
Igor Puzanov
Igor Puzanov Roswell Park Cancer Institute
John Nemunaitis
John Nemunaitis Gradalis (United States)
Kevin J. Harrington
Kevin J. Harrington Royal Marsden NHS Foundation Trust
Merrick I. Ross
Merrick I. Ross The University of Texas MD Anderson Cancer Center
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
F. Stephen Hodi
F. Stephen Hodi Harvard University
Lisa H. Butterfield
Lisa H. Butterfield University of California, San Francisco
Jeffrey Schlom
Jeffrey Schlom National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in immunology, exploring related healthcare degrees can open diverse career opportunities. Many students start with foundational nursing programs, such as online ABSN programs for non nurses. These accelerated courses are designed for individuals transitioning into nursing from other fields, providing a fast but thorough route into patient care and clinical practice.

When considering accelerated options, it’s important to understand that some come with more accessible admissions criteria. Resources highlighting the easiest accelerated nursing programs can help applicants identify programs that balance rigor with attainable entry requirements.

Beginning a nursing career might also involve enrolling in programs with simpler acceptance processes. For example, LPN schools easy to get into offer practical and practical nursing training that can serve as a stepping stone to advanced degrees in healthcare and immunology research.

Advancing further, some pursue specialized roles through nurse practitioner degrees. Exploring the what is the easiest NP program resources allows students to find programs that offer manageable entry into this expert level of nursing, which often intersects with immunology in clinical and research settings.

Best Scientists Citing Howard L. Kaufman

Trending Scientists